Table 4 Assessment of potential pharmacokinetic drug interactions

From: Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

Dosing regime

N

Cmax/Cmax, ss (ng ml−1)

AUC/AUCss (ng .h ml−1)

Saracatinib alone

9

590 (38.4)

10600 (43.8)

Saracatinib+carboplatin+paclitaxel

9

545 (42.2)

9990 (35.5)

Ratio of saracatinib in combination/alone

9

0.923 (0.675–1.25)

0.940 (0.774–1.23)

Carboplatina without saracatinib

4

33600 (20.4)

64933 (24.8)

Carboplatina in combination with saracatinib

4

36500 (15.5)

73867 (16.0)

Ratio of carboplatina with/without saracatinib

4

1.087 (0.898–1.53)

1.14 (0.921–1.67)

Paclitaxelb without saracatinib

6

2970 (35.4)

9850 (22.8)

Paclitaxelb in combination with saracatinib

6

2840 (22.2)

10100 (20.9)

Ratio of paclitaxelb with/without saracatinib

6

0.957 (0.682–1.82)

1.02 (0.871–1.51)

  1. Abbreviations: AUCss=area under the plasma concentration–time curve during any dosing interval at steady state (for saracatinib); AUC=area under the plasma concentration–time curve (for carboplatin and paclitaxel); Cmax, ss=maximum plasma concentration at steady state (for saracatinib); Cmax=maximum plasma concentration (for carboplatin and paclitaxel); N=number subjects used to calculate parameters. Parameters are expressed as geometric mean (coefficient of variation, %); ratios are geometric mean (range).
  2. aIn combination with paclitaxel.
  3. bIn combination with carboplatin.
Back to article page